Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

48 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes.
Sathyanarayana P, Jogi M, Muthupillai R, Krishnamurthy R, Samson SL, Bajaj M. Sathyanarayana P, et al. Obesity (Silver Spring). 2011 Dec;19(12):2310-5. doi: 10.1038/oby.2011.152. Epub 2011 Jun 9. Obesity (Silver Spring). 2011. PMID: 21660077 Clinical Trial.

Pioglitazone reduced fasting plasma glucose (FPG) (P < 0.05), fasting free fatty acid (FFA) (P < 0.05), and HbA(1c) (Δ = 1.0%, P < 0.01), while increasing plasma adiponectin concentration by 86% (P < 0.05). Hepatic fat (magnetic resonance s

Pioglitazone reduced fasting plasma glucose (FPG) (P < 0.05), fasting free fatty acid (FFA) (P < 0.05), and HbA(1c) (Δ =

Effect of short-term free Fatty acids elevation on mitochondrial function in skeletal muscle of healthy individuals.
Chavez AO, Kamath S, Jani R, Sharma LK, Monroy A, Abdul-Ghani MA, Centonze VE, Sathyanarayana P, Coletta DK, Jenkinson CP, Bai Y, Folli F, Defronzo RA, Tripathy D. Chavez AO, et al. Among authors: sathyanarayana p. J Clin Endocrinol Metab. 2010 Jan;95(1):422-9. doi: 10.1210/jc.2009-1387. Epub 2009 Oct 28. J Clin Endocrinol Metab. 2010. PMID: 19864449 Free PMC article. Clinical Trial.

RESULTS: Compared with saline infusion, lipid infusion reduced whole-body glucose uptake by 22% (P < 0.05). Psi(m) decreased by 33% (P < 0.005) after lipid infusion and the decrement in Psi(m) correlated with change in plasma FFA after lipid infusion (r = 0.75

RESULTS: Compared with saline infusion, lipid infusion reduced whole-body glucose uptake by 22% (P < 0.05). Psi(m) decreased by 33

The effect of pioglitazone treatment on 15-epi-lipoxin A4 levels in patients with type 2 diabetes.
Gutierrez AD, Sathyanarayana P, Konduru S, Ye Y, Birnbaum Y, Bajaj M. Gutierrez AD, et al. Among authors: sathyanarayana p. Atherosclerosis. 2012 Jul;223(1):204-8. doi: 10.1016/j.atherosclerosis.2012.04.016. Epub 2012 May 7. Atherosclerosis. 2012. PMID: 22687642 Clinical Trial.

RESULTS: PIO 15 increased plasma 15-epi-LXA(4) levels (0.63 ± 0.06-1.05 ± 0.08 ng/mL, p < 0.01) and adiponectin levels (6.4 ± 0.3-10.1 ± 0.7 μg/mL, p < 0.001) and decreased fasting plasma glucose (125 ± 8-106 ± 9 mg/dL, p < 0.05), free fatty acids (F

RESULTS: PIO 15 increased plasma 15-epi-LXA(4) levels (0.63 ± 0.06-1.05 ± 0.08 ng/mL, p < 0.01) and adiponectin levels (6.4 ± 0.3-

Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial.
Samson SL, Sathyanarayana P, Jogi M, Gonzalez EV, Gutierrez A, Krishnamurthy R, Muthupillai R, Chan L, Bajaj M. Samson SL, et al. Among authors: sathyanarayana p. Diabetologia. 2011 Dec;54(12):3093-100. doi: 10.1007/s00125-011-2317-z. Epub 2011 Sep 29. Diabetologia. 2011. PMID: 21956711 Free PMC article. Clinical Trial.
NF-kappaB-inducing kinase (NIK) mediates skeletal muscle insulin resistance: blockade by adiponectin.
Choudhary S, Sinha S, Zhao Y, Banerjee S, Sathyanarayana P, Shahani S, Sherman V, Tilton RG, Bajaj M. Choudhary S, et al. Among authors: sathyanarayana p. Endocrinology. 2011 Oct;152(10):3622-7. doi: 10.1210/en.2011-1343. Epub 2011 Aug 16. Endocrinology. 2011. PMID: 21846802 Free PMC article.
Increased abundance of the adaptor protein containing pleckstrin homology domain, phosphotyrosine binding domain and leucine zipper motif (APPL1) in patients with obesity and type 2 diabetes: evidence for altered adiponectin signalling.
Holmes RM, Yi Z, De Filippis E, Berria R, Shahani S, Sathyanarayana P, Sherman V, Fujiwara K, Meyer C, Christ-Roberts C, Hwang H, Finlayson J, Dong LQ, Mandarino LJ, Bajaj M. Holmes RM, et al. Among authors: sathyanarayana p. Diabetologia. 2011 Aug;54(8):2122-31. doi: 10.1007/s00125-011-2173-x. Epub 2011 May 12. Diabetologia. 2011. PMID: 21562756 Free PMC article.
After bariatric surgery in morbidly obese participants with subsequent weight loss, skeletal muscle APPL1 abundance was significantly reduced (p < 0.05) in association with an increase in plasma adiponectin (p < 0.01), increased levels of ADIPOR1 (p &lt …
After bariatric surgery in morbidly obese participants with subsequent weight loss, skeletal muscle APPL1 abundance was significantly reduce …
Interaction of hematopoietic progenitor kinase 1 and c-Abl tyrosine kinase in response to genotoxic stress.
Ito Y, Pandey P, Sathyanarayana P, Ling P, Rana A, Weichselbaum R, Tan TH, Kufe D, Kharbanda S. Ito Y, et al. Among authors: sathyanarayana p. J Biol Chem. 2001 May 25;276(21):18130-8. doi: 10.1074/jbc.M007294200. Epub 2001 Jan 30. J Biol Chem. 2001. PMID: 11278340
Role of apoptosis of renal tubular cells in acute renal failure: therapeutic implications.
Rana A, Sathyanarayana P, Lieberthal W. Rana A, et al. Among authors: sathyanarayana p. Apoptosis. 2001 Feb-Apr;6(1-2):83-102. doi: 10.1023/a:1009680229931. Apoptosis. 2001. PMID: 11321045 Review.
Correction: Mixed lineage kinase 3 promotes breast tumorigenesis via phosphorylation and activation of p21-activated kinase 1.
Das S, Nair RS, Mishra R, Sondarva G, Viswakarma N, Abdelkarim H, Gaponenko V, Sathyanarayana P, Rana B, Rana A. Das S, et al. Among authors: sathyanarayana p. Oncogene. 2020 Jan;39(3):722. doi: 10.1038/s41388-019-1011-3. Oncogene. 2020. PMID: 31530933
Cholesterol promotes Cytolysin A activity by stabilizing the intermediates during pore formation.
Sathyanarayana P, Maurya S, Behera A, Ravichandran M, Visweswariah SS, Ayappa KG, Roy R. Sathyanarayana P, et al. Proc Natl Acad Sci U S A. 2018 Jul 31;115(31):E7323-E7330. doi: 10.1073/pnas.1721228115. Epub 2018 Jul 16. Proc Natl Acad Sci U S A. 2018. PMID: 30012608 Free PMC article.
48 results
Jump to page
Feedback